Changzhou Raj Biological Pharmaceutical

Regie Biology is a clinical-stage biotechnology company focused on the development of mRNA-based vaccines and therapeutics. The company has developed a proprietary mRNA technology platform and a lipid nanoparticle (LNP) delivery system to address infectious diseases, oncology, and protein replacement therapies. Its lead candidate, RH109, is a lyophilized mRNA COVID-19 vaccine that has demonstrated stability at room temperature and is undergoing clinical evaluation. Headquartered in Changzhou with R&D centers in Shenzhen and Wuhan, Regie Biology aims to leverage its integrated R&D and manufacturing capabilities to deliver innovative genomic medicines. The company is backed by prominent investors and continues to expand its pipeline into diverse therapeutic areas.